United Capital Financial Advisors LLC Takes $2.37 Million Position in Cencora, Inc. $COR

United Capital Financial Advisors LLC bought a new stake in shares of Cencora, Inc. (NYSE:COR) in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 8,387 shares of the company’s stock, valued at approximately $2,373,000.

Several other large investors have also added to or reduced their stakes in the stock. United Bank increased its position in shares of Cencora by 4.5% during the second quarter. United Bank now owns 7,032 shares of the company’s stock valued at $2,109,000 after buying an additional 305 shares during the period. Nebula Research & Development LLC purchased a new position in shares of Cencora during the 2nd quarter worth approximately $595,000. Treasurer of the State of North Carolina raised its position in shares of Cencora by 7.9% in the 2nd quarter. Treasurer of the State of North Carolina now owns 85,534 shares of the company’s stock worth $25,647,000 after acquiring an additional 6,244 shares in the last quarter. Diversify Advisory Services LLC lifted its stake in shares of Cencora by 94.1% in the 2nd quarter. Diversify Advisory Services LLC now owns 2,585 shares of the company’s stock valued at $747,000 after purchasing an additional 1,253 shares during the period. Finally, DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main boosted its position in shares of Cencora by 26.0% during the second quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 73,452 shares of the company’s stock valued at $22,025,000 after purchasing an additional 15,154 shares in the last quarter. Institutional investors own 97.52% of the company’s stock.

Insider Transactions at Cencora

In other news, EVP Elizabeth S. Campbell sold 11,300 shares of the company’s stock in a transaction dated Monday, August 24th. The shares were sold at an average price of $324.12, for a total transaction of $3,662,556.00. Following the completion of the sale, the executive vice president owned 19,455 shares of the company’s stock, valued at $6,305,754.60. This represents a 36.74% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Lauren M. Tyler acquired 550 shares of the stock in a transaction dated Monday, June 22nd. The stock was acquired at an average price of $270.23 per share, for a total transaction of $148,626.50. Following the purchase, the director directly owned 4,359 shares in the company, valued at approximately $1,177,932.57. This trade represents a 14.44% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders own 0.38% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have recently weighed in on COR. Citigroup reaffirmed a “buy” rating on shares of Cencora in a research report on Thursday, August 6th. Bank of America raised their target price on shares of Cencora from $280.00 to $285.00 and gave the company a “neutral” rating in a research note on Wednesday, June 24th. JPMorgan Chase & Co. boosted their price target on Cencora from $382.00 to $390.00 and gave the stock an “overweight” rating in a research report on Friday, August 7th. Morgan Stanley raised their price objective on Cencora from $342.00 to $346.00 and gave the company an “overweight” rating in a research report on Friday, August 7th. Finally, Royal Bank Of Canada started coverage on Cencora in a research note on Wednesday, August 19th. They set a “sector perform” rating and a $330.00 price objective for the company. Thirteen analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat.com, Cencora presently has a consensus rating of “Moderate Buy” and an average target price of $370.85.

Cencora Trading Up 0.3%

NYSE:COR opened at $322.12 on Friday. The company has a market cap of $61.47 billion, a PE ratio of 23.93, a price-to-earnings-growth ratio of 1.84 and a beta of 0.57. The company has a current ratio of 0.93, a quick ratio of 0.58 and a debt-to-equity ratio of 3.53. The company has a 50 day simple moving average of $307.38 and a two-hundred day simple moving average of $310.88. Cencora, Inc. has a 12 month low of $244.82 and a 12 month high of $377.54.

Cencora (NYSE:COR) last released its quarterly earnings results on Wednesday, August 5th. The company reported $4.48 earnings per share for the quarter, beating the consensus estimate of $4.35 by $0.13. Cencora had a return on equity of 125.45% and a net margin of 0.79%.The firm had revenue of $84.75 billion for the quarter, compared to analysts’ expectations of $84.31 billion. During the same period in the prior year, the firm earned $4.00 EPS. The company’s revenue was up 5.1% compared to the same quarter last year. Research analysts forecast that Cencora, Inc. will post 17.87 earnings per share for the current year.

Cencora announced that its board has approved a stock repurchase program on Thursday, May 21st that authorizes the company to repurchase $2.00 billion in shares. This repurchase authorization authorizes the company to repurchase up to 3.9% of its stock through open market purchases. Stock repurchase programs are often a sign that the company’s board of directors believes its stock is undervalued.

Cencora Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, August 31st. Shareholders of record on Friday, August 14th will be given a $0.60 dividend. This represents a $2.40 annualized dividend and a yield of 0.7%. The ex-dividend date of this dividend is Friday, August 14th. Cencora’s dividend payout ratio (DPR) is presently 17.83%.

Cencora Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.